Brean Murray Carret & Co. Starts InterMune Inc. (ITMN) at Buy; Undervalued EU Opportunity
Tweet
Share
E-mailGet Alerts ITMN Hot Sheet
Price: $73.89 --0%
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Rating Summary:
8 Buy, 9 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 9 | New: 24
Join SI Premium – FREE
Brean Murray Carret & Co. initiates coverage on InterMune Inc. (NASDAQ: ITMN) with a Buy. PT $50.
Brean analyst says, "ITMN is beginning to launch Esbriet, a newly approved drug for the treatment of a fatal disease, IPF, in the European Union. We believe the market opportunity for Esbriet can peak at $1 billion per year."
For more ratings news on InterMune Inc. click here and for the rating history of InterMune Inc. click here.
Shares of InterMune Inc. closed at $35.47 yesterday.
Brean analyst says, "ITMN is beginning to launch Esbriet, a newly approved drug for the treatment of a fatal disease, IPF, in the European Union. We believe the market opportunity for Esbriet can peak at $1 billion per year."
For more ratings news on InterMune Inc. click here and for the rating history of InterMune Inc. click here.
Shares of InterMune Inc. closed at $35.47 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Starts Faraday Copper Corp (FDY:CN) (CPPKF) at Buy
- Jefferies Starts Trekor Metals (TKO:CN) (TGB) at Buy
- JPMorgan Starts Logitech International SA (LOGN:SW) (LOGI) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
